Category: AHFS PMI

AHFS Patient Medication Information Update – October 2017

19 October, 2017 no responses

The October update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Fosaprepitant Injection (Emend®)
    • Fosaprepitant injection is used along with other medications to prevent nausea and vomiting in adults that may occur within 24 hours after receiving cancer chemotherapy treatment. It is also used along with other medications to prevent delayed nausea and vomiting that may occur several days after receiving certain chemotherapy medications.
  • Enasidenib (Idhifa®)
    • Enasidenib is used to treat a certain type of acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells) that has worsened or come back after treatment with other chemotherapy medications.
  • Inotuzumab Ozogamicin Injection (Besponsa®)
    • Inotuzumab ozogamicin injection is used to treat certain acute lymphoblastic leukemia (ALL; a type of cancer that begins in the white blood cells) in adults who have not responded to previous cancer treatments.
  • Glecaprevir and Pibrentasvir (Mavyret®)
    • The combination of glecaprevir and pibrentasvir is used to treat certain types of chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus).

FDA MedWatch Alert Revisions

  • Obeticholic Acid (Ocaliva®)
    • FDA is warning that the liver disease medicine obeticholic acid is being incorrectly dosed in some patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death.
  • Methadone (Dolophine®) & Buprenorphine (Subutex®)
    • FDA is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system (CNS).

AHFS Patient Medication Information Update – September 2017

20 September, 2017 no responses

The September update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Neratinib (Nerlynx®)
    • Neratinib is used to treat a certain type of hormone receptor-positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in adults after treatment with trastuzumab (Herceptin®) and other medications.
  • L-glutamine (Endari®)
    • L-glutamine is used to is used to reduce the frequency of painful episodes (crises) in adults and children 5 years of age and older with sickle cell anemia (an inherited blood disorder in which the red blood cells are abnormally shaped [shaped like a sickle] and cannot bring enough oxygen to all parts of the body).
  • Guselkumab Injection (Tremfya®)
    • Guselkumab injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in people whose psoriasis is too severe to be treated by topical medications alone.
  • Sofosbuvir, Velpatasvir, and Voxilaprevir (Vosevi®)
    • The combination of sofosbuvir, velpatasvir, and voxilaprevir is used to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in adults who have already received other HCV treatments.
  • Abaloparatide Injection (Tymlos®)
    • Abaloparatide injection is used to treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (‘change in life,’ end of menstrual periods), who are at high risk of fractures (broken bones) or who could not be treated successfully with other medications.

FDA MedWatch Alert Revisions

  • Sodium Polystyrene Sulfonate (Kayexalate®)
    • FDA is recommending that patients avoid taking the potassium-lowering drug sodium polystyrene sulfonate at the same time as other medicines taken by mouth.
  • Pembrolizumab Injection (Keytruda®)
    • FDA is warning about the risks associated with the use of pembrolizumab in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. Pembrolizumab is not approved for treatment of multiple myeloma.

AHFS Patient Medication Information Update – August 2017

28 August, 2017 no responses

The August update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Midostaurin (Rydapt®)
    • Midostaurin is used with other chemotherapy drugs to treat certain types of acute myeloid leukemia (AML; a type of cancer of the white blood cells). Midostaurin is also used to certain types of mastocytosis (a blood disorder in which there are too many mast cells [a certain kind of white blood cell]).
  • Sarilumab Injection (Kevzara®)
    • Sarilumab injection is used alone or with other medications to treat rheumatoid arthritis (RA: condition in which the body attacks its own joints causing pain, swelling, and loss of function).

FDA MedWatch Alert Revisions

  • None
1 2 3 … 5
© 2022, American Society of Health-System Pharmacists®. All rights reserved.